Global Chemotherapy Induced Peripheral Neuropathy Treatment Market – Industry Trends and Forecast to 2029

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By  Treatment (Medication, Therapy, Others), Drug Class (Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Others), Drug Type (Branded, Generic), End-User (Hospitals, Research Institutes, Specialty Clinics),  Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis and Size

As per the data provided by the Centers for Disease Control and Prevention (CDC), in the U.S., 1,708,921 new cancer cases were witnessed in 2018 and 599,265 people died of cancer. The demand for chemotherapy has increased worldwide with the increasing burden of cancer. Peripheral neuropathy includes symptoms that result from damage to the peripheral nerves. Chemotherapy and several other medications are used to treat cancer that can cause peripheral neuropathy.

Data Bridge Market Research analyses a growth rate in the global chemotherapy induced peripheral neuropathy treatment market in the forecast period 2022-2029. The expected CAGR of global chemotherapy induced peripheral neuropathy treatment market tend to be around 5.66% in the mentioned forecast period. The market was valued at USD 967.73 million in 2021, and it would grow upto USD 1503.28 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Scope and Segmentation

Market Definition

Chemotherapy induced peripheral neuropathy is a severe type of clinical condition induced by the number of chemotherapeutics drugs or cytotoxic drugs such as platinum, vinca alkaloids, taxanes, eribulin, epothilones and bortezomib. All these drugs cause altered pathological problem to the neurons. The pathological problems lead to the degeneration of peripheral sensory and motor nerves that can cause patients to have sensory disturbances, balance problems or weakness.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics

Drivers

• Increase in Advanced Treatments

The rising advanced treatment methods are boosting in the market growth. Advanced cancer treatments improve patient survival and surge the number of patients who needs long-term outpatient chemotherapy. More exposure to chemotherapy may result in a rising number of these diseased cases, thus driving the chemotherapy-induced peripheral neuropathy market growth. Thus, it acts as a major driver in the market growth.

• Increasing Prevalence of Cancer

It has been witnessed that for every 100,000 people, 436 new cancer cases were seen and 149 people died of cancer. According to the data published by International Agency for Research on Cancer (IARC), 22,81,658 new cancer cases were witnessed in 2020 in the U.S., where breast cancer was predominant, accounting for 11.1% of all reported cases. This boosts the market growth.

Opportunities

• Increase in Smoking and Lifestyle Changes

Cigarette smoking is one of the leading cause of preventable disease and death in the U.S. It  accounts for more than 480,000 deaths every year. In addition to this, the lifestyle changes that are attained by today’s population such as unhealthy lifestyle, poor diet, stress and many such factors altogether contribute to the developing opportunities of the market.

• Growing Initiatives by Market Players

The rising initiatives by several market players are creating in much opportunities for the market growth. For instance, In March 2020, Regenacy Pharmaceuticals announced the closing of a US$ 30 million Series A financing. This initiative was co-led by Cobro Ventures and Taiwania Capital Management Corporation, with the active participation of Yonjin Capital, 3E Bioventures Capital, VIVA Biotech Holdings, and TA YA VENTURE HOLDINGS LIMITED, and other several undisclosed private investors.  

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to perform these treatments could limit the growth of the global chemotherapy induced peripheral neuropathy treatment market over a forecast period.

• High Cost

The huge expenditure required for the treatment processes hamper the market growth. High costs are associatred with chemotherapy regimens, which somewhat hamper the market's growth.

This global chemotherapy induced peripheral neuropathy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chemotherapy induced peripheral neuropathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Chemotherapy Induced Peripheral Neuropathy Treatment Market

 COVID-19 has left a major global public health crisis that has impacted practically every market sector. Its long-term consequences are expected to boost the industry growth during the forecast period.

The load on healthcare facilities and professionals was increasing with the rapid surge in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the global chemotherapy induced peripheral neuropathy treatment market. The pandemic has put a strain on the treatment procedures in general. As a result of the lockdown and travel restrictions, the number of hospitals has decreased and countless drives have been cancelled around the world.

Recent Developments:

• In December 2020, for the development of ricolinostat, Regenacy announced a joint venture with 3E Bioventures in China, which will be further followed by a U.S.-based phase 2 study in patients with painful diabetic peripheral neuropathy and other peripheral neuropathies. This collaboration will evaluate the efficacy and safety of ricolinostat in patients having chemotherapy-induced peripheral neuropathy in China.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Scope

The global chemotherapy induced peripheral neuropathy treatment market is segmented on the basis of drug class, drug type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Nerve Protective Therapy
• Anti-Inflammatory Therapy
• Neurotransmitter Based Therapy
• Antioxidant
• Others

Treatment

• Medication
• Therapy
• Others

Drug Type

• Branded
• Generic

End-User

• Hospitals
• Research Institutes
• Specialty Clinics

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Chemotherapy Induced Peripheral Neuropathy Treatment Market Regional Analysis/Insights

The global chemotherapy induced peripheral neuropathy treatment market is analyzed and market size insights and trends are provided by drug class, drug type, treatment, distribution channel and end-user as referenced above.

The major countries covered in the global chemotherapy induced peripheral neuropathy treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market in the forecast period due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment.

Asia-Pacific is expected to have the largest market share over coming years for the chemotherapy-induced peripheral neuropathy treatment market due to the constant rise in cancer incidence with increased demand for cost-efficient therapeutics.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Analysis

The global chemotherapy induced peripheral neuropathy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global chemotherapy induced peripheral neuropathy treatment market.

Key players operating in the global chemotherapy induced peripheral neuropathy treatment market include:

• Alexion Pharmaceuticals, Inc. (U.S.)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Vertex Pharmaceuticals Incorporated (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• Amgen Inc. (U.S.)
• Jazz Pharmaceuticals, Inc. (U.K.)
• Asahi Kasei Pharma Corporation (Japan)
• Solasia Pharma K.K. (Japan)
• Immunepharma.com. (U.S.)